Neurotech International Ltd. (AU:NTI) has released an update.
Neurotech International Ltd, a biopharmaceutical company focusing on pediatric neurological disorders, has issued new shares under certain conditions exempt from investor disclosure and is currently embroiled in a legal dispute with Dolce Cann Global Pty Ltd. The company strongly denies allegations of breaching a licence agreement related to the use of specific cannabis strains for medicinal purposes. Neurotech is actively conducting clinical trials, including a Phase II/III study on Autism Spectrum Disorder and has received ethical clearance for a trial in spastic cerebral palsy.
For further insights into AU:NTI stock, check out TipRanks’ Stock Analysis page.
